"CONCLUSIONS
Patients with relapsed or refractory multiple myeloma who received a combination of elotuzumab, lenalidomide, and dexamethasone had a significant relative reduction of 30% in the risk of disease progression or death. (Funded by Bristol-Myers Squibb and AbbVie Biotherapeutics; ELOQUENT-2 ClinicalTrials.gov number,NCT01239797.)"
http://www.nejm.org/doi/full/10.1056/NEJMoa1505654
No comments:
Post a Comment